This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01335477
First received: April 13, 2011
Last updated: June 24, 2016
Last verified: June 2016
Results First Received: November 14, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double-Blind;   Primary Purpose: Treatment
Condition: Pulmonary Fibrosis
Interventions: Drug: placebo
Drug: BIBF 1120

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Oral administration of Placebo matching nintedanib soft gelatine capsules
Nintedanib 150 mg Bid

Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).

Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.


Participant Flow:   Overall Study
    Placebo   Nintedanib 150 mg Bid
STARTED   220   331 
COMPLETED   179   272 
NOT COMPLETED   41   59 
Adverse Event                30                42 
Non compliant with protocol                0                2 
Lost to Follow-up                1                2 
Consent withdrawn, not due to AE                7                9 
Not treated                1                2 
Reason other than those stated above                2                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Treated Set (TS): The TS consisted of randomized patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.

Reporting Groups
  Description
Placebo Oral administration of Placebo matching nintedanib soft gelatine capsules
Nintedanib 150 mg Bid

Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).

Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.

Total Total of all reporting groups

Baseline Measures
   Placebo   Nintedanib 150 mg Bid   Total 
Overall Participants Analyzed 
[Units: Participants]
 219   329   548 
Age 
[Units: Years]
Mean (Standard Deviation)
 67.1  (7.5)   66.4  (7.9)   66.6  (7.8) 
Gender 
[Units: Participants]
     
Female   48   73   121 
Male   171   256   427 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.   [ Time Frame: 52 weeks ]

2.  Secondary:   Change From Baseline in Saint George’s Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks   [ Time Frame: Baseline and 52 weeks ]

3.  Secondary:   Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation   [ Time Frame: 52 weeks ]

4.  Secondary:   Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks   [ Time Frame: Baseline and 52 weeks ]

5.  Secondary:   Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks   [ Time Frame: Baseline and 52 weeks ]

6.  Secondary:   Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks   [ Time Frame: Baseline and 52 weeks ]

7.  Secondary:   Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks   [ Time Frame: Baseline and 52 weeks ]

8.  Secondary:   Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold   [ Time Frame: Baseline and 52 weeks ]

9.  Secondary:   Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold   [ Time Frame: Baseline and 52 weeks ]

10.  Secondary:   FVC Responders Using 10% Threshold at 52 Weeks   [ Time Frame: 52 weeks ]

11.  Secondary:   Proportion of FVC Responders Using 5% Threshold at 52 Weeks   [ Time Frame: 52 weeks ]

12.  Secondary:   Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

13.  Secondary:   Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

14.  Secondary:   Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

15.  Secondary:   Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

16.  Secondary:   Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

17.  Secondary:   Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

18.  Secondary:   Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

19.  Secondary:   Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)   [ Time Frame: baseline and 52 weeks ]

20.  Secondary:   Proportion of Patient’s Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)   [ Time Frame: 52 weeks ]

21.  Secondary:   Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)   [ Time Frame: baseline, 12 weeks, 24 weeks and 52 weeks ]

22.  Secondary:   Risk of an Acute IPF Exacerbation Over 52 Weeks   [ Time Frame: 52 weeks ]

23.  Secondary:   Time to Death Over 52 Weeks   [ Time Frame: 52 weeks ]

24.  Secondary:   Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)   [ Time Frame: 52 weeks ]

25.  Secondary:   Time to On-treatment Death   [ Time Frame: 52 weeks ]

26.  Secondary:   Time to Death or Lung Transplant Over 52 Weeks   [ Time Frame: 52 weeks ]

27.  Secondary:   Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.   [ Time Frame: 52 weeks ]

28.  Secondary:   Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks   [ Time Frame: baseline and 52 weeks ]

29.  Secondary:   Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks   [ Time Frame: baseline and 52 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim
phone: 1-800-243-0127
e-mail: clintriage.rdg@boehringer-ingelheim.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01335477     History of Changes
Other Study ID Numbers: 1199.34
2010-024252-29 ( EudraCT Number: EudraCT )
Study First Received: April 13, 2011
Results First Received: November 14, 2014
Last Updated: June 24, 2016